“Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties - The Lancet” plus 1 more

“Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties - The Lancet” plus 1 more

Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties - The Lancet

Posted: 29 Oct 2020 04:36 PM PDT

[unable to retrieve full-text content]Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties  The Lancet

DRIVE ReDIRECT: Program Seeks to Develop Countermeasures Against Chemical Threats - Global Biodefense

Posted: 31 Oct 2020 02:40 PM PDT

The rapid availability of effective medical countermeasures against chemical exposures, from either accidents or chemical weapons attack, is critical in the treatment of their acute health effects following exposures.

The ReDIRECT Program is a new initiative from the Biomedical Advanced Research and Development Authority (BARDA) which aims to identify existing, commonly available therapeutics that can be used to save lives during a chemical emergency.

Under this new EZ BAA Area of Interest (AOI), BARDA will review concise abstract submissions for funding development that repurposes easily accessible therapeutics as medical countermeasures against threats such as chlorine gas, opioids, nerve agents, and others.

The ideal medical countermeasure is easily administered in a mass-casualty situation and has rapid efficacy as a post-exposure therapy, which requires easy access within hospitals, pharmacies, and the community. Drug repurposing, or label expansion, is a strategy that is used to identify new uses for FDA approved or late-stage investigational therapeutics that are outside of their original clinical indication. The identification of existing compounds for repurposing holds the potential to expand current response capabilities to chemical threats, as well as potentially mitigating the costs and risks associated with conventional drug discovery.

Repurposing drugs will ensure that these therapeutics are easily accessible during an emergency and reduce the reliance on centralized stockpiles or logistically-challenging forward deployment programs. Candidates for repurposing will focus on treating the symptoms associated with exposure to the chemical threat, rather than the agent.

The ReDIRECT program is focused on repurposing therapeutics against any of the following agents:

Pulmonary Agents: Development of medical countermeasures to prevent and treat lung damage (including pulmonary edema, pneumonitis, and fibrosis) resulting from exposure to agents such as chlorine, sulfur mustard and phosgene.

Opioids: Development of medical countermeasures to treat life-threatening respiratory depression caused by opioid overdose. These post-exposure treatments should be quick-acting and effective against a variety of opioids, including synthetic opioids such as Fentanyl. Candidates should have a mechanism of action different from existing opioid receptor antagonists.

Vesicants: Development of medical countermeasures that limit harmful aspects of exposure to vesicating agents such as sulfur mustard and Lewisite. Particular preference is given to drugs with potential to ameliorate the long term effects of exposure including Mustard Gas Keratopathy.

Blood/Metabolic Agents: Development of medical countermeasures to treat acute poisoning from agents such as cyanides. Antidotes should be easily administered by first responders in personal protective equipment. Preference is given to those cyanide antidotes that are also effective against smoke inhalation-related exposure.

Nerve Agents and Organophosphorus (OP) Pesticides: Development of medical countermeasures to treat life-threatening and long-term effects of nerve agents and OP pesticides. Antidotes should be easily administered by first responders in personal protective equipment.

Computational approaches to identify candidates for drug repurposing: Development of improved methods to rapidly identify FDA approved or late stage candidate compounds that can be repurposed against any of the aforementioned chemical threats.

The effort is a collaboration of BARDA's Division of Research, Innovation, and Ventures (DRIVe) and the Chemical, Biological, Radiological and Nuclear (CBRN) Division.

The EZ-BAA was created to provide a streamlined process through which BARDA, and DRIVe specifically, can review and accept applications for development funding of transformative products and technologies to protect Americans from health security threats. The application process is both business-friendly and easy to follow.

Since its inception, the EZ-BAA has helped transform BARDA's contracting process and provide innovators, entrepreneurs, and organizations with a simplified and rapid mechanism to partner with the BARDA.

For additional information, see solicitation BAA-20-100-SOL-0002.

Comments

Post a Comment

Popular posts from this blog

“Opioids in America, Part 3: The other side of the crisis - Greeley Tribune” plus 1 more

Image
“Opioids in America, Part 3: The other side of the crisis - Greeley Tribune” plus 1 more Opioids in America, Part 3: The other side of the crisis - Greeley Tribune Posted: 31 Oct 2020 04:20 PM PDT Editor's Note: This is Part 3 of a three-part series looking into the opioid epidemic across the U.S., rehabilitation options in Weld County and stories from people who have overcome or are currently fighting addiction to opioids. Like many things, there's another side to the opioid crisis. While the addiction to opioids is a problem that needs to be addressed, people who are using the drugs exclusively as prescribed — and who still truly need it from a medical perspective — have been swept up in what some have seen as government's knee-jerk reaction to the crisis. In having their ability limited to get the drugs they need in order to function, many of these patients are left suffering debilitating pain. Richard Mark VanWormer w
Read more

“Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study - The Lancet” plus 4 more

Image
“Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study - The Lancet” plus 4 more Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study - The Lancet Evaluation of the novel coronavirus disease in Turkish children: Preliminary outcomes - Wiley Coronavirus recovery: Most common post-COVID signs which could indicate signs of long term trouble - Times of India What you – and doctors – should watch for if you have COVID-19 - The Conversation US Coronavirus in San Diego and California: Latest updates and news - CBS News 8 Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study - The Lancet Posted: 08
Read more

“Ground glass opacity: Causes, symptoms, and treatments - Medical News Today” plus 1 more

Image
“Ground glass opacity: Causes, symptoms, and treatments - Medical News Today” plus 1 more Ground glass opacity: Causes, symptoms, and treatments - Medical News Today Posted: 30 Mar 2021 03:14 AM PDT Ground glass opacity (GGO) refers to the hazy gray areas that can show up in CT scans or X-rays of the lungs. These gray areas indicate increased density inside the lungs. The term comes from a technique in glassmaking during which the surface of the glass is blasted by sand. This technique gives the glass a hazy white or frosted appearance. There are many potential causes of GGO, including infections, inflammation , and growths. One 2020 review also found that GGO was the most common anomaly among people with COVID-19-related pneumonia. This article will look at what GGO is, some of its causes, and its treatment options. GGO refers to gray areas that can show up in lung X-rays or CT scans . Normally, the lungs appear black
Read more